FDA issues EUA for monoclonal antibody treatments for COVID-19

Editor's Note

The Food & Drug Administration, on February 9, issued an emergency use authorization (EUA) for Eli Lilly’s (Indianapolis, Indiana) combination therapy of two antibodies, bamlanivimab and etesevimab.

The authorization is for the two antibodies to be administered together for treatment of mild to moderate COVID-19 in adults and children 12 years of age or older, and who are at high risk for progressing to severe COVID-19.

The EUA also includes treatment for those 65 years of age or older or who have certain chronic medical conditions.